


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31200356</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1540-1413</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the National Comprehensive Cancer Network : JNCCN</Title>
                <ISOAbbreviation>J Natl Compr Canc Netw</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>750-757</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.6004/jnccn.2019.7310</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">jnccn18522</ELocationID>
            <Abstract>
                <AbstractText>The use of immune checkpoint inhibitors (ICIs) is rapidly expanding to the treatment of many cancer types, both in the metastatic setting and as an adjuvant to other therapies. Clinical trials using ICIs have largely excluded patients with preexisting autoimmune diseases due to concerns for increased toxicity. However, emerging evidence shows that ICIs may be considered in some patients with autoimmunity. This review discusses the commonalities between clinical autoimmune diseases and ICI-induced immunotherapy-related adverse events, and summarizes the existing case series that describes patients with solid tumors who have a preexisting autoimmune disease. This review also discusses which patients with autoimmunity could be considered reasonable candidates for ICI therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kennedy</LastName>
                    <ForeName>Laura C</ForeName>
                    <Initials>LC</Initials>
                    <AffiliationInfo>
                        <Affiliation>aDepartment of Medicine, Division of Oncology, University of Washington, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>bClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhatia</LastName>
                    <ForeName>Shailender</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>aDepartment of Medicine, Division of Oncology, University of Washington, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>bClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>aDepartment of Medicine, Division of Oncology, University of Washington, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>bClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grivas</LastName>
                    <ForeName>Petros</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>aDepartment of Medicine, Division of Oncology, University of Washington, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>bClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Natl Compr Canc Netw</MedlineTA>
            <NlmUniqueID>101162515</NlmUniqueID>
            <ISSNLinking>1540-1405</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200356</ArticleId>
            <ArticleId IdType="doi">10.6004/jnccn.2019.7310</ArticleId>
            <ArticleId IdType="pii">jnccn18522</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

